Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Schuurhuis, Gerrit J., Heuser, Michael, Freeman, Sylvie, Béné, Marie-Christine, Buccisano, Francesco, Cloos, Jacqueline, Grimwade, David, Haferlach, Torsten, Hills, Robert K., Hourigan, Christopher S., Jorgensen, Jeffrey L., Kern, Wolfgang, Lacombe, Francis, Maurillo, Luca, Preudhomme, Claude, van der Reijden, Bert A., Thiede, Christian, Venditti, Adriano, Vyas, Paresh, Wood, Brent L., Walter, Roland B., Döhner, Konstanze, Roboz, Gail J., Ossenkoppele, Gert J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Special Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865231/
https://ncbi.nlm.nih.gov/pubmed/29330221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-801498
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia